Physicochemical Properties
| Molecular Formula | C22H25NO5S |
| Molecular Weight | 415.502605199814 |
| Exact Mass | 415.145 |
| CAS # | 1228439-36-8 |
| Related CAS # | (+)-KCC2 blocker 1;1228439-71-1 |
| PubChem CID | 46866400 |
| Appearance | Light yellow to khaki solid powder |
| LogP | 2.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 29 |
| Complexity | 687 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [C@]1(CC2C=CC(S(C)(=O)=O)=CC=2)(C(=O)OCC2C=CC=CC=2)CCCN1C(C)=O |
| InChi Key | XFXZWVGQXNFWDE-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C22H25NO5S/c1-17(24)23-14-6-13-22(23,21(25)28-16-19-7-4-3-5-8-19)15-18-9-11-20(12-10-18)29(2,26)27/h3-5,7-12H,6,13-16H2,1-2H3 |
| Chemical Name | benzyl 1-acetyl-2-[(4-methylsulfonylphenyl)methyl]pyrrolidine-2-carboxylate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | KCC2 blocker 1 (compound 13; 100 μM) reduced NKCC1 activity by 35%. |
| ln Vivo | KCC2 Blocker 1 (Compound 13; 1 mg/kg IV and 6 mg/kg PO) has a t1/2 of 0.3 hours, a CL of 26 mL/min/kg, a Cmax of 457 ng/mL, and an AUC in males Wistar rats are 726 ng·h/mL[1]. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rat[1] Doses: 1 mg/kg or 6 mg/kg (pharmacokinetic/PK/PK analysis) Route of Administration: IV (1 mg/kg) and PO (6 mg/kg) Experimental Results: t1 /2 is 0.3 hrs (hrs (hours)), CL is 26 mL/min/kg, C max is 457 ng/mL, and AUC is 726 ng·h/mL. |
| References |
[1]. Benzyl prolinate derivatives as novel selective KCC2 blockers. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2542-5. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~601.68 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (5.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4067 mL | 12.0337 mL | 24.0674 mL | |
| 5 mM | 0.4813 mL | 2.4067 mL | 4.8135 mL | |
| 10 mM | 0.2407 mL | 1.2034 mL | 2.4067 mL |